QDEL vs. NTLA, CLDX, MYGN, VIVO, HSKA, XRAY, MMSI, HAE, NEOG, and ICUI
Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Intellia Therapeutics (NTLA), Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), Meridian Bioscience (VIVO), Heska (HSKA), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), Neogen (NEOG), and ICU Medical (ICUI). These companies are all part of the "medical" sector.
QuidelOrtho (NASDAQ:QDEL) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.
QuidelOrtho received 20 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. However, 69.42% of users gave Intellia Therapeutics an outperform vote while only 67.28% of users gave QuidelOrtho an outperform vote.
99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 1.0% of QuidelOrtho shares are owned by insiders. Comparatively, 3.0% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
QuidelOrtho presently has a consensus target price of $59.00, suggesting a potential upside of 45.71%. Intellia Therapeutics has a consensus target price of $66.77, suggesting a potential upside of 191.06%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than QuidelOrtho.
QuidelOrtho has a net margin of -61.65% compared to Intellia Therapeutics' net margin of -893.34%. QuidelOrtho's return on equity of 3.96% beat Intellia Therapeutics' return on equity.
QuidelOrtho has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.
In the previous week, QuidelOrtho had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 18 mentions for QuidelOrtho and 13 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.87 beat QuidelOrtho's score of 0.14 indicating that Intellia Therapeutics is being referred to more favorably in the news media.
QuidelOrtho has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.
Summary
QuidelOrtho and Intellia Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get QuidelOrtho News Delivered to You Automatically
Sign up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
QuidelOrtho Competitors List
Related Companies and Tools
